Clinical trials: Itching, open to volunteers
Lichen Simplex Chronicus
A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07619183
- Testing
- PG-033 tablets
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Dry Skin
Evaluation of the Effect of Combined Use of Cosmetic Products for Dry and Itchy Skin.
The goal of this study is to learn if combined use of shower oleogel and body lotion works to improve skin itching and dryness in adults. It will also learn about its safety.
- Trial name
- NCT07695805
- Testing
- Shower oleogel and body lotion, Shower gel and body lotion
- Where
- Portugal
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Pregnancy Related, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
- Trial name
- NCT06627335
- Testing
- Ruxolitinib Cream, TCS
- Where
- United States
- Volunteers
- 5,621 people
- Sponsor
- Incyte Corporation
Pruritus
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies…
- Trial name
- NCT05263206
- Testing
- Dupilumab, Fexofenadine (loratadine if not available)
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 284 people
- Sponsor
- Sanofi
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07700056
- Testing
- Remibrutinib
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Tinea Pedis
A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes.
- Trial name
- NCT07668999
- Testing
- ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
Lichen Simplex Chronicus
A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of single ascending oral doses(SAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07013097
- Testing
- PG-033
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Primary Sclerosing Cholangitis (PSC)
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
- Trial name
- NCT06699121
- Testing
- LB-P8 low-dose, LB-P8 high-dose
- Where
- 7 sites in United States
- Volunteers
- 87 people
- Sponsor
- LISCure Biosciences
Epidermolysis Bullosa (EB)
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry.
- Trial name
- NCT07482787
- Testing
- SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Paradigm Therapeutics
Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin)
A Clinical Trial to Evaluate the Effects of the NeuEve Dryness Treatment Kit on Vaginal Health, Comfort, and Quality of Life in Postmenopausal Women
This is a decentralized, single-group, open-label clinical trial evaluating a 12-week regimen of the NeuEve Dryness Treatment Kit (comprising Feminine Moisture Support oral softgels, Bone Support oral capsules, NeuEve Salve…
- Conditions
- Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin), Improves Vaginal Wall Thickness, Reduces Pain During Sex
- Trial name
- NCT07893795
- Testing
- Intervention
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NeuEve
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07811869
- Testing
- Remibrutinib
- Where
- 10 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Pruritus
J-LINX: Japan LINerixibat eXtension Study
This study evaluates the long-term safety and tolerability of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and…
- Trial name
- NCT07860710
- Testing
- Linerixibat
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Chronic Spontaneous Urticaria
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3…
- Trial name
- NCT07256392
- Testing
- barzolvolimab, Standard of Care
- Where
- 201 sites in United States, Argentina and 28 more
- Volunteers
- 1,370 people
- Sponsor
- Celldex Therapeutics
Tinea Pedis
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
This study is designed to evaluate the safety and effectiveness of multiple 1% tolnaftate formulations delivered through novel stick-based vehicles in individuals with tinea pedis (athlete's foot).
- Trial name
- NCT07245667
- Testing
- 1% Tolnaftate Stick Formula A, 1% Tolnaftate Stick Formula B, 1% Tolnaftate Stick Formula C
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Propedix, Inc.
Pruritus, Primary Biliary Cholangitis
TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of TH104 in primary biliary cholangitis (PBC) participants with moderate to severe pruritus.
- Trial name
- NCT06733519
- Testing
- Nalmefene
- Volunteers
- 40 people
- Sponsor
- Tharimmune Inc
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Pregnancy Related, Atopic Dermatitis
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during…
- Trial name
- OPERA-1 (NCT06259669)
- Testing
- Ruxolitinib Cream
- Where
- United States
- Volunteers
- 958 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis, Pruritus
Observational Analytical Validation Study of the Replior ScratchSense
Nocturnal scratching is a frequent and meaningful symptom in dermatological conditions such as atopic dermatitis. It may reflect underlying disease activity and can substantially disrupt overall sleep and quality of life.
- Conditions
- Atopic Dermatitis, Pruritus, Chronic Pruritus of Unknown Origin
- Trial name
- NCT07909967
- Testing
- Scratch and sleep research tracking
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Replior AB
Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
In patients with Alagille syndrome (ALGS), the key objectives are to evaluate the tolerability, long-term safety (including possible liver toxicity) and long-term efficacy of Livmarli treatment.
- Trial name
- NCT07290257
- Testing
- Livmarli Oral Product
- Where
- 15 sites in Belgium, France and 6 more
- Volunteers
- 230 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Chronic Pruritus of Unknown Origin
Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin
The goal of this clinical trial is to assess the efficacy and safety of ATTO-1310 in patients with chronic pruritus/itch of unknown origin.
- Trial name
- NCT07833306
- Testing
- ATTO-1310
- Volunteers
- 300 people
- Sponsor
- Attovia Therapeutics Inc